Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate
450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg
extended release tablet under fed conditions using a single-dose, randomized,
three-treatment, three-period, six-sequence crossover design.